Adding a Targeted Treatment Option for Prostate Cancer
The FDA has expanded the use of the PARP-targeted therapeutic olaparib to include the treatment of certain patients with...
Progress Against Cancer
The FDA has expanded the use of the PARP-targeted therapeutic olaparib to include the treatment of certain patients with...
The FDA has approved a new molecularly targeted therapeutic for treating certain patients who have advanced gastrointestinal stromal tumors. he...
The FDA has expanded the use of a molecularly targeted therapeutic to include the treatment of certain patients with...
The FDA has approved a combination of nivolumab and ipilimumab to treat certain patients with metastatic lung cancer. The...
The FDA has expanded the use of an immunomodulatory therapeutic to include the treatment of adults who have Kaposi...
The FDA has approved an alternative dosing schedule for the immune checkpoint inhibitor pembrolizumab. On April 28, 2020, the...
The FDA approved a new molecularly targeted therapeutic for certain patients with lung cancer driven by a mutation in...
The FDA has approved a type of molecularly targeted therapeutic called an antibody-drug conjugate for the treatment of metastatic...
The FDA has approved a new molecularly targeted therapeutic for treating certain patients with advanced or metastatic HER2-positive breast...
The first molecularly targeted therapeutic for use in the treatment of bile duct cancer has been approved by the...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn MoreYour donation to the American Association for Cancer Research helps our more than 47,000 members worldwide drive progress against cancer.
Donate Today